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Abstract: The diagnosis and management of pneumococ-
cal disease remains challenging, in particular in children 
who often are asymptomatic carriers, and in low-income 
countries with a high morbidity and mortality from febrile 
illnesses where the broad range of bacterial, viral and par-
asitic cases are in contrast to limited, diagnostic resources. 
Integration of multiple markers into a single, rapid test is 
desirable in such situations. Likewise, the development 
of multiparameter tests for relevant arrays of pathogens 
is important to avoid overtreatment of febrile syndromes 
with antibiotics. Miniaturization of tests through use of 
micro- and nanotechnologies combines several advan-
tages: miniaturization reduces sample requirements, 
reduces the use of consumables and reagents leading 
to a reduction in costs, facilitates parallelization, ena-
bles point-of-care use of diagnostic equipment and even 
reduces the amount of potentially infectious disposables, 
characteristics that are highly desirable in most health-
care settings. This critical review emphasizes our vision 
on the importance of multiparametric testing for diagnos-
ing pneumococcal infections in patients with fever and 
examines recent relevant developments in micro/nano-
technologies to achieve this goal.
Keywords: immunoassays; microfluidics; nanodiagnos-
tics; nanotechnology; pneumococcal disease; point-of-
care; rapid tests.
Introduction
Streptococcus pneumoniae (pneumococcus) is a Gram-
positive bacterium that is a major cause of infectious 
diseases including pneumonia, empyema, sepsis, otitis 
media and meningitis. Pneumococcal infections occur 
more frequently in the elderly or the very young. Infec-
tion may point to an underlying compromise of the host’s 
immune system but infection can also result from an 
overwhelming inoculum or a particularly virulent strain. 
Asymptomatic carriage in the nasopharynx occurs in 
children below the age of 10 years with a reported preva-
lence of 30%–60% but is also found in 1%–10% of adults 
(1). In economically deprived populations and in devel-
oping countries, these carriage rates are often higher (2). 
Here, the detection of the pathogen in the nasopharynx 
alone, is therefore not sufficient to diagnose a clini-
cal infection. Thus, another parameter is required here 
to identify the pathogen which emphasizes the need of 
multiparameter tests.
Streptococcus pneumoniae has several virulent factors 
(Figure 1 and Table 1) and at least 93 different serotypes are 
identified (14) the prevalence of which changes over time 
and differs between geographic locations (15), thus adding 
some critical potential to the challenge of reliable diagno-
sis using a single diagnostic assay. Diagnosis is important 
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because untreated disease (e.g. pneumonia, sepsis, men-
ingitis) may be lethal. Specific treatment is available and 
may be life-saving when applied early. Current diagnostic 
options are shown in Figure 2. A clinical syndrome com-
patible with pneumococcal disease is typically worked up 
with radiographs and antigen testing in developed coun-
tries, but in resource poor countries, diagnosis of pneu-
monia, meningitis and sepsis is often based on clinical 
algorithms only (16). The resulting overuse of antibiotics is 
believed to contribute to the development of antibacterial 
drug resistance.
In this critical review we briefly discuss common 
diagnostic methods (detection of antigens, nucleic acids 
and serologic response) and illustrate these with relevant 
achievements (including recent) that were felt to be impor-
tant. This will be followed by the timeline of testing in a 
clinical context. In the final part of this work, we present 
emerging diagnostics that use micro/nanotechnology such 
as micro/nanoparticles, microsensors, and microfluidic 
devices. Here, the focus is also on new techniques that might 
lead to a new era of diagnostics for pneumococcal infections.
Figure 1: Schematic representation of S. pneumoniae and its  virulent 
factors [with permission from textbook in Diagnosis, Serotyping, 
Virulence Factors and Enzyme-linked Immunosorbent Assay (ELISA) 
for Measuring Pneumococcal Antibodies.” (2nd version) Statens 
Serum Institut, Denmark (3)].
Original articles and reviews published from January 
2000 to April 2016 were identified by keyword search in 
PubMed, ScienceDirect and Scopus using the keywords 
“pneumococcus”, “pneumococcal infection”, “pneumo-
coccal antigens”, “nanotechnology” and following links 
in identified articles. Articles cited in the review were 
selected by the authors based on their perceived relevance 
for the target audience of this journal.
Microscopy and blood culture
The microscopic appearance and colony morphology is 
used in most clinical laboratories to identify S. pneumo-
niae. Under the microscope, the Gram-positive bacteria 
is visible as slightly pointed cocci that are usually found 
in pairs, but also in short chains or as single bacteria. On 
blood agar plates, most serotypes of this microorganism 
form small round doughnut shaped colonies. Serotype 3 
and 37 typically form large mucoid colonies (17).
Streptococcus pneumoniae is capable of producing 
α-hemolysis on blood agar plates, which produces a green 
color. Other species as Streptococcus mitis and Streptococ-
cus oralis also have this characteristic and they are often 
referred as the viridans group (18). Thus additional specific 
characteristics of S. pneumoniae are required to exclude 
most viridans species such as optochin susceptibility and 
catalase negativity (18, 19). Bile solubility might be used, 
however, some exceptions are known (20). Thus, identifying 
S. pneumoniae on phenotype alone is not adequate enough.
Detecting antigens, nucleic acids 
and serology
Antigens
Teichoic acids or cell wall polysaccharides
Teichoic acids, found in Gram-positive bacteria, are bac-
terial polysaccharides of ribitol-, or glycerol-phosphate 
that are linked via phosphodiester bonds. These anionic 
glycopolymers, known as cell wall polysaccharide (CWPS), 
play a key role in antibiotic resistance (21). CWPS can be 
detected by the commercial Binax NOW (Alere, Global) 
rapid urinary antigen test, with a clinical test  performance 
reported in a meta-analysis (22). The majority of included 
patients were adults and had suspected community- 
acquired  pneumonia (CAP); data comparing the Binax 
NOW test against any reference test were analyzed. In 
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Table 1: Top, a description of important virulent factors of S. pneumoniae. 
Virulent factor   Molecular weight  Description   Type
Capsular polysaccharide (CPS)   –   Outermost layer of S. pneumonia ±200–400 nm thick; prevents 
phagocytosis; 93 serotypes (4)
  Polysaccharide
Theichoic acids: also called cell 
wall polysaccharide (CWPS)
  –   Common cell wall polysaccharide; tetrasaccharide units, joined 
together through ribitol phosphate diester and contains one or 
two phosphocholine subsituents (4)
  Polysaccharide
Lipoteichoic acid   –   Also called F-antigen; polysaccharide part (same as CWPS) 
linked to diacylated glycerol via glucose residue (4)
  Polysaccharide
Pneumolysin   53 kDa   Pore-forming protein capable of causing lysis and activation of 
complement (5)
  Protein
Pneumococcal surface protein A 
(PspA)
  67–99 kDa   Bound to cell surface through CWPS/choline attached; inhibits 
opsonisation and phagocytosis through binding complement 
component C3 (6, 7)
  Protein
Pneumococcal surface protein C 
(PspC)
  75 kDa   Bound to cell surface through CWPS/choline attached protein; 
mediates adherence to host by recognizing sialic acid on 
epithelial cells (8, 9)
  Protein
Pneumococcal surface adhesin A 
(PsaA)
  37 kDa   Membrane bound; ABC-type transport protein complex; 
transports Mn2+, plays role in attachment to host cell and 
virulence (10)
  Lipoprotein
N-acetylmuramoyl-L-alanine 
amidase (Autolysin)
  36 kDa   In cell envelope, degrades peptidoglycan in cell wall leading to 
lysis and release of pneumolysin. Is activated by bile (11)
  Enzyme
Neuraminidase A and B [NanA and 
NanB)
  108 kDa (NanA) 
75 kDa (NanB)
  Sialidase that cleaves the terminal sialic acids from 
glycoproteins, glycolipids and oligosaccharides on the cell 
surface and in the mucus (12)
  Enzyme
IgAI protease   –   Capable of cleaving human immunoglobulin A1 (IgA1) (13)   Enzyme
O
O
O
O
O
O
O
O
O
O
CWPS. Tetrasaccharide units. R=H or COCH3
OCH2CH2N(CH3)2
O
H
H
H H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
OH
OH
OH
O
O
P
P
nO
–
O–
H HNHRNHAc
NHAc
NHR
CH3
H
OH
OH
OH
OH
OH
HO
 
Protein structure pneumolysin
On the bottom (right), the structure formula of the tetrasaccharide units of CWPS and (left) a 3D protein structure of pneumolysin [image 
with permission from the RCSB PDB (www.rcsb.org) of PDB ID 2bk1. [Tilley SJ, Orlova EV, Gilbert RJ, Andrew PW, Saibil HR. “Structural basis 
of pore formation by the bacterial toxin pneumolysin.” Cell 2015;121:247–56].
children, a high rate of false positives due to the carrier 
status of pneumococci was found, rendering the test less 
useful in this setting. In 12 out of the 27 studies, the ref-
erence standard was a combination of blood culture, 
sputum (culture or smear) and culture of another respira-
tory sample (e.g. nasopharyngeal, transthoracic needle 
aspirate). Bivariate meta-analysis resulted in an overall 
sensitivity of 68.5% and a specificity of 84.2% for the Binax 
NOW test. The inclusion of all 27 selected studies with 
positive blood culture alone as reference test yielded a sen-
sitivity of 74.0% and a specificity of 97.2%. Other investi-
gators reported that false negative results may arise with 
low CWPS levels while false positive results may result due 
to cross-reaction, for example shortly after an infection, in 
nasopharyngeal carriage or in the presence of S. mitis and/
or S. oralis species carrying closely related CWPS (23).
Capsular polysaccharides (CPS)
Capsular polysaccharides (CPS) form the outermost layer 
of the pneumococcal wall and their variability results in 
93 known serotypes. CPS are detectable in the urine of 
patients and asymptomatic carriers during, after infection 
and even after vaccination. Antibodies against CPS are 
protective rendering CPS suitable as vaccines.
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Microscopy
Detection of Gram-
positive diplococci in
body fluids. Specific but
requires infra structure
and skilled personel
Biopsy or bronchoscopy
Specific but depending on infra-sturuture. Requires
skilled personel. Biopsy: invasive or semi invasive to
get high quality samples for testing by other methods
Clinical symptoms & signs
e.g. respiratory distress, tachypnea,
cough. Radiologic evidence is often
sought. Sensitivity & specificity is
limited
Antigen & nucleic acid detection
e.g. Rapid-point-of-care tests, ELISA,
MALDI-TOF, RT-PCR. Sensitivity &
specificity is depending on method
Bacterial cultures
e.g. of blood, pulmonary
secretions. Specific but
time consuming
Diagnosing
pneumococcal
infection
Figure 2: A schematic overview of the different possibilities to diagnose pneumococcal disease.
A multiplexed immunoassay was developed, employ-
ing microspheres and based on the Luminex system, 
which permits detection of 13 different serotypes in urine 
with a limit of detection of 0.6–8.8 pg/mL (24). A clinical 
sensitivity and specificity of 97% and 100% was achieved 
when testing urine samples in the subset of patients with 
a positive blood culture for S. pneumoniae and an X-ray 
confirmed CAP. Pickering and Hill (25) present a protocol 
to measure the antibodies after vaccination with the 23 
valent pneumococcal polysaccharide vaccine based on 
the Luminex xMAP (Luminex Corporation, Austin, TX, 
USA) microsphere-based liquid assay. Sensitivities and 
specificities are not included.
Serotyping pneumococci by CPS detection in urine 
or other fluids such as nasopharyngeal secretions is also 
possible with the latex agglutination test. A protocol for 
agglutination reagents with serotype specific antibod-
ies from antisera on polystyrene latex particles is avail-
able (26). This low-cost protocol is easy to use, includes 
quality control and allows storage for a year at 2–8°C, 
and is therefore suited also for resource-constrained 
settings.
Pneumolysin
The intracellular pore forming toxin pneumolysin is a 53 
kDa conserved protein released upon LytA (autolysin) 
lysis that contributes to the invasiveness of the strain. 
Pneumolysin detection in sputum, urine, cerebrospinal 
fluid and blood indicates pneumococcal infection (27).
The value of pneumolysin detection in urine was 
investigated and compared to the Binax NOW test in adults 
and children in another investigation (28). The pneumoly-
sin ELISA required 3 h processing time. One hundred and 
eight patients with blood culture confirmed pneumococcal 
infections were tested. In adults, sensitivity and specificity 
were 56.6% and 92.2%, respectively. Pneumolysin concen-
tration in urine decreased after the initiation of treatment. 
Notably, pneumolysin was not detected in children with 
only nasopharyngeal colonization, leading to enhanced 
specificity. In colonized children, sensitivity and speci-
ficity of pneumolysin was 62.5% and 94.4%, respectively, 
while Binax NOW had a sensitivity and specificity of 87.5% 
and 27.8%, respectively. For non-colonized children, the 
sensitivity and specificity of the pneumolysin ELISA was 
68.7% and 94.1%, respectively, while the Binax NOW test 
had a sensitivity of 93.7% and a specificity of 41.2% (28).
In another investigation, the Binax NOW test was 
used to detect pneumolysin in cerebrospinal fluid (CSF) 
and compared to culture and latex agglutination (29). 
1173 CSF samples of five countries in Africa and Asia, 
collected from patients between 1 and 59  months old. 
From these patients, n = 69, were confirmed by culture on 
pneumococcal meningitis and the Binax NOW test was 
found to be positive in 98.6%. By using the test on culture 
positive samples for bacterial meningitis caused by 
other pathogens (n = 125), the test was negative in 99.3%. 
When only the latex agglutination tests and culture was 
used, pneumococci were detected from 7.4% in Asia to 
15.6% in Africa, including the Binax Now test resulted 
in 16.2% in Africa (Nigeria) to 20% in Asia (Bangladesh). 
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These results suggested the underestimation of pneumo-
cocci infections in the past.
Other pneumococcal antigens
Pneumococcal surface adhesin A is an immunogenic, 
37 kDa surface lipoprotein expressed by all pneumococci. 
It is highly conserved among pneumococcal serotypes, 
and is also present in S. anginosus, S. mitis and S. oralis 
with a sequence similarity of 90%, 94% and 95% com-
pared to S. pneumoniae serotype 6B (30), limiting its diag-
nostic value.
Others investigated surface proteins are the pneumo-
coccal surface protein A (PspA), family 1 and 2, and the 
pneumococcal surface protein C (PspC). PspC, present in 
75% of pneumococcal strains, is related to PspA, but has 
a specific N-terminal region interfering with the comple-
ment system through binding of the complement factor 
H. The Hic protein, (factor H-binding inhibitor of comple-
ment), is a PspC variant mainly found in serotype 3 (31). 
The homology between these proteins renders their spe-
cific discrimination difficult and may limit their value as a 
diagnostic biomarker.
The triggering receptor expressed on myeloid cells 
(sTREM1), has been reported as a promising marker for 
infection (32), and has a decent correlation with blood 
culture positivity in a univariate meta-regression analysis 
of 13 studies. The pooled sensitivity and specificity was 
84% and 77%, respectively, for the diagnosis of lower res-
piratory tract infection with similar diagnostic accuracy 
for community-acquired infection and hospital acquired 
infection in subgroup analysis.
The search for new potential biomarkers by using 
mass spectroscopy-based proteomic analysis in African 
children provided two valuable candidates: lipocalin-2 
and haptoglobin (33). Lipocalin-2 discriminated non-
severe and non-bacterial from severe and bacterial pneu-
monia and the authors hypothesize that the use of this 
marker, embedded in a point-of-care-test in combination 
with haptoglobin measurement, could distinguish severe 
pneumonia from malaria and viral lung infection.
Nucleic acids
Pneumococcal nucleic acids can be detected by amplifi-
cation technologies. The polymerase chain reaction (PCR) 
amplifies a selected region of the target gene, but is chal-
lenged by the homology of genes between species and 
the occurrence of false positive results in asymptomatic 
carriers. Strain-specific primers focusing on non- 
homologous DNA regions may improve the specificity of 
amplification tests. An example of pitfalls of homology 
among bacterial species, is the pneumolysin gene ply as 
reported by Song et al (17). Samples originating from the 
lower respiratory tract of patients with pneumococcal 
disease were tested and yielded sensitivities between 68% 
and 100% and poor specificities. However, throat swabs of 
patients with community acquired pneumonia and from 
control subjects resulted in similar rates of test positivity 
of ~55%–58% for the ply gene (34). Another example is the 
lytA gene that is present in pneumococci as well as in strep-
tococci, but varies less among streptococci. Others found 
that in ~2% of the investigated pneumococcal strains a 
mutation is present that is resulting in a negative PCR test 
(20). This test is still applicable in routine laboratories but 
needs confirmation in case of a negative result. To distin-
guish between α-hemolytic streptococci and pneumococci 
the bile test might be used. The cell wall of pneumococci is 
bile soluble (and therefore resulting in lysis), where as all 
α-hemolytic streptococci are not. However, the 2% pneu-
mococci carrying the mutation in the lytA gene are also 
bile insoluble and thus providing a false negative result.
Thus, strain specific primers may be of high impor-
tance for certain microorganisms and might improve 
the sensitivity and specificity of an amplification test. A 
high-throughput method for serotype specific quantifi-
cation and molecular serotyping of pneumococci using 
a nanofluidics based RT-PCR system was developed (35). 
Primer pairs were designed such that over 50 serotypes 
are covered. Their performance is comparable to the 
conventional PCR-based assays. Recently, a novel quan-
titative real-time PCR was developed to detect 40 major 
pneumococci serotypes worldwide directly in blood and 
nasopharyngeal specimens (36). This work presents 
newly designed primers and probes based on targets 
that were already described by Pai et  al. (37). The most 
frequent serotypes found in Brazilian, French and South 
African (see Figure 3) samples were 14, 1 and 7A/F and 3 
and 19F, respectively. In case both blood and nasopharynx 
samples were available, the serotype in blood was always 
present together with other serotypes in the nasopharynx. 
This highly sensitive assay was capable of detecting  < 100 
CFU/mL and opens the door to large-scale epidemiologi-
cal studies of pneumococci. Other scientists (38) pub-
lished a novel quantitative PCR assay for the detection 
of S. pneumoniae. The target is the competence regulator 
gene comX, which exists in duplicate copies in S. pneu-
moniae and not in other bacterial species. Validation of 
the assay was done on DNA extracted from serum of 30 
patients with blood cultures positive for S. pneumoniae 
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and 51 serum samples positive for other bacteria. The LytA 
quantitative PCR assay was used to compare. The clini-
cal sensitivity was 47% for both assays and the diagnos-
tic specificity was 98.2% and 100% for LytA and comX, 
respectively (38).
Serology
The detection of serotype specific antibodies (CPS) can 
be done by ELISA, the Neufeld Quellungs test and the 
latex agglutination test [see also Streptococcus pneu-
moniae Textbook, Statens Serum Institut, Copenhagen, 
Denmark (3)].
Immune response against, for example, PspA, PspC 
and Hic are known, but titers do not sufficiently discrimi-
nate patients from healthy controls, with the exception of 
PspA that shows a significant titer increase in the conva-
lescence phase. Cross-reactivity between the antibodies 
for PspA and PspC are also reported (39, 40). Multiparam-
eter testing is probably required for correct result interpre-
tation in this situation.
A validation study for a multiplexed set of antigens 
causing respiratory tract disease was performed where 
fluorescent bead based multiplexed immunoassay quan-
tifies IgG against a panel of microorganisms including 
S.  pneumoniae, Haemophilus influenzae and Moraxella 
catarrhalis. For each marker a singleplex measurement 
was compared with the multiplex assay, and the pneu-
mococci multiplex was compared with an ELISA of 22 
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Figure 3: Pneumococcal load distribution in nasopharyngeal 
samples from the South African cohort.
Each plot represents a sample and the mean bacterial concentra-
tion for each group is indicated by the bold bars (Student’s t-test, 
p < 0.001). Invasive and non-invasive serotypes are compared upon 
presence in nasopharyngeal samples en whole blood. [Messaoudi 
et al. (36); http://dx.doi.org/10.1371/journal.pone.0151428.g002.]
pneumococcal antibodies containing serum samples that 
had been analyzed previously. The reproducibility, speci-
ficity and correlation were validated for six pneumococ-
cal antigens [Ply, PspA1, PspA2, choline binding protein 
A (CbpA), pneumococcal choline binding protein A (PcsA) 
and pneumococcal histidine triad protein D (PhtD)]. The 
assay had a specificity above 92% and some cross-reac-
tivity between PspA1, PspA2 and CbpA was reported. The 
serum samples of 50 children were also examined and 
revealed a wide range of antibody concentrations and 
increases in samples of recovering patients (41).
Time line of testing
Applying a test in the right time slot of infection is critical 
for its clinical benefit and its interpretation. Blood culture 
testing is more sensitive early in infection, but becomes 
rapidly negative after treatment with antibiotic therapy. 
Recently, a strategy was proposed to identify various bac-
teria including pneumococci within 6  h after signaling 
growth in blood culture (42). Directly from the positive 
blood cultures, rapid agglutination tests were performed 
and showed a very high predictive value. Such early diag-
nosis allows faster treatment adjustment in serious bacte-
rial infection. Negative tests were repeated after colonies 
grew for further 4–6 h.
DNA based detection of pneumococci in serum 
was found to be particularly sensitive when the disease 
was more severe than uncomplicated pneumonia, and 
claimed that such testing gives additional diagnostic ben-
efits to blood cultures including: 1) better disease severity 
assessment, 2) antibiotic streamlining and 3) detection 
of  invasive pneumococcal disease after initiation of 
 antibiotics (43).
Others investigated the use of a urinary test after start-
ing an empiric antibiotic treatment and concluded that 
this has a potential to guide the right choice of medical 
treatment of pneumococcal disease in adults at an earlier 
stage (44). From this we conclude that combining existing 
and new test modalities may lead to new improved diag-
nostic strategies/management.
Towards multiparameter testing
Multiparameter testing includes the notion of determin-
ing multiple parameters for a particular infectious agent, 
and also the concept of testing for multiple pathogens in 
a single test. An important technique here, which evolved 
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rapidly last decade, is the use of matrix-assisted laser 
desorption ionization time-of-flight (MALDI-TOF) mass 
spectrometry (MS) in the clinic. This technique enables 
the rapid detection of bacteria and fungi in  < 1  h when 
starting with pure bacteria culture. The advantage is 
that there is no knowledge of the pathogen required in 
advance, however, the disadvantage is that a pure culture 
is required and with this sufficient equipped laboratory 
and trained personnel. Thus, for most resource poor coun-
tries this is not an option. Fall et al. (45), presented the use 
of MALDI-TOF in Dakar (Senegal) where it was success-
fully used to identify species causing infectious diseases 
in tropical Africa.
While testing in febrile disease in developed coun-
tries often yields an abundance of parameters from a fully 
equipped central lab as mentioned above, multiparameter 
testing in a simple and inexpensive fashion is a pressing 
need in particular for these countries. Mortality and mor-
bidity resulting from infectious diseases are still highest in 
sub-Saharan Africa and in low-income countries of south-
east Asia. The relative frequency of fever episodes due to 
pneumococcal disease, malaria, typhoid fever, dengue, 
or chikungunya may change with age, with season, as a 
function of geography, and may be related to local disease 
outbreaks. Currently, blind treatment is associated with 
high costs and microbial resistance development, while 
systematic testing is economically unrealistic in many 
areas. The recent emergence of global viral threats includ-
ing new influenza subtypes, dengue virus, Middle East 
respiratory syndrome coronavirus and Ebola add an addi-
tional urgency to the development of rapid, bedside, low-
cost tests that discriminate between multiple alternative 
causes of fever.
There is evidence that availability of multiple diag-
nostic parameters may enhance the diagnosis of pneu-
mococal disease. The combination of a positive urinary 
Binax Now antigen test combined with measurement 
of CRP and PCT in plasma was evaluated in children 
( < 6 years) (46). Diagnostic accuracy for predicting pneu-
mococcal CAP (without positive urine test) for PCT alone 
(cut-off ≥ 1.5  ng/mL) was limited, having a sensitivity of 
94.4% and a specificity of 52.6% whereas for CRP (cut-
off ≥ 100 mg/L) the sensitivity was 91.9% and the specific-
ity 60.5%. In combination with a positive urine test (same 
cut-offs), sensitivity and specificity were 65.5% and 85.7% 
for PCT, and 65.5% and 88.6% for CRP, respectively. Thus, 
in case of an emergency consultation such a combination 
is a useful tool to predict presumed pneumococcal CAP. 
Applied to examine pleural fluid samples of children, the 
Binax NOW had a sensitivity of 71%–96% and a specific-
ity of 71%–100% for pneumococcal empyema (47–50). 
Recent publications show progress in miniaturization of 
diagnostic technologies, paving the way to multiparam-
eter testing by integration of multiple assays into a single 
device or test substrate [for further reading see (51, 52)].
Micro/nanotechnology diagnostic 
innovations
Both micro- and nanotechnology has significantly con-
tributed to new therapies, drugs and diagnostics during 
the last 5–10 years. In this paragraph, we only focus on 
new developments that might be used to improve or to 
develop new diagnostics for the detection of a pneumo-
coccal infection.
The separation of bacteria from blood (or urine) may 
be done by, e.g. filtration, centrifugation and sedimenta-
tion. However, the key limitation for S. pneumoniae is that 
the number in colony forming units (i.e. viable bacteria) 
in blood cultures is known to be low and high sensitiv-
ity is improbable except when a large volume of blood is 
separated. The use of microfluidic devices may largely 
improve the capability to separate or concentrate bacte-
ria prior the use of other diagnostic methods and tests. 
For example, the work of Park et al. (53), who developed 
a microfluidic device for the continuous dielectropho-
retic separation and concentration of bacteria from crude 
biologic samples. They showed a 104 concentration of 
target cells and provided a separation efficiency of 94.3% 
in human CSF and 87.2% in blood for Escherichia coli. Ai 
et al. (54) used a microfluidic device and surface acoustic 
waves across the channels and demonstrated the separa-
tion of E. coli bacteria from peripheral blood. Another pos-
sibility is size-based cell sorting by the use of an ordered 
array of obstacles. This is also called deterministic lateral 
displacement. A combination of grooves and protrusions 
in a microfluidic device could successfully separate, 3D 
spherical particles, red blood cells (2D planar shaped) 
and rod shaped bacteria. The bacteria investigated in 
this work were: E. coli (rod-shaped or bacillus), K. pneu-
moniae (rod shaped), S. epidermidis (spherical or coccus) 
and Pseudomonas  aeruginosa (rod-like or coccobacillus) 
(55). The final example is the work of Kang et al. (56) who 
presented a method to selectively detect bacteria directly 
from milliliters of diluted blood in one step. Droplet micro-
encapsulation of diluted blood was done by using a micro-
fluidic device and a high throughput 3D particle counter 
system. Specific DNA enzymes were used as sensor to the 
selected target E. coli. The fluorophore attached the DNA 
enzyme will be released from its quencher upon binding 
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and subsequently generate a fluorescent signal. The limit 
of detection was 1–10 CFU/mL. To conclude, the use of 
microfluidic techniques to separate and/or concentrate 
and detect bacteria is promising but needs to be further 
developed for challenging bacteria as S. pneumococci. In 
addition, the above mentioned is mainly applicable in 
developed countries.
Micro- and nanoparticles are nowadays widely used 
in lateral flow tests (rapid tests) that are in most cases 
based on sandwich immunoassays. Here, the presence 
of an antigen or antibody in a liquid sample (e.g. blood, 
serum, plasma, urine and CSF) leads to the immobiliza-
tion of micro/nanoparticles and a visible signal. Exam-
ples of used particles are gold nanoparticles, colored 
latex beads, magnetic particles, carbon nanoparticles. 
Important here is that all materials should retain their 
properties once conjugated to biomolecules and should 
be easily detectable at a concentration near the diagnostic 
threshold. [For further reading, see Refs. (57–59).] Lateral 
flow tests for the detection of pneumococcal already exist, 
however, an option would be to develop multiparameter 
tests as mentioned in the previous paragraph (46).
Wu and coworkers (60) presented a novel detection 
system based on quantum dots and microbeads that was 
developed to detect target DNA of pathogenic bacteria. 
On microbeads DNA hairpin structures are coupled. The 
composition of these hairpin oligonucleotides includes: 
a poly-T linker, a Tag sequence, the barcode region and 
an anti-Tag sequence. The barcode region is composed 
of four words each of four nucleotides (61) and has a 
unique design used for each species. Then, two types 
of probes are used: the internal probe, which has a 
complementary sequence to the barcode region and a 
reporter probe that has a sequence complementary to 
the anti-Tag region. Both probes have quantum dots in 
two different emission spectra. Legionella spp. is used 
as an example microorganism. The method exists of four 
steps, 1) the DNA hairpin structures on the microbeads 
will be denatured at 95°C, then 2) the provided linear oli-
gonucleotide microbeads will hybridize with the dena-
tured DNA samples (Legionella spp.) and will prevent 
the recovery of the hairpin structures, 3) the linear oligo-
nucleotides will now be able to hybridize with both the 
internal as the reporter probes. When the target DNA is 
not present, the hairpin structure will recover. The fluo-
rescence intensity of the reporter probes may be used to 
quantify the target DNA. The limit of detection was 0.1 
ng of the extracted DNA and 10 CFU/test. This method 
is very useful for the multiplex detection of serotypes of 
S. pneumoniae, however, will only be available for well-
equipped laboratories.
Veigas et  al. (62) showed for the first time that by 
functionalizing a single Au-nanoprobe with multiple 
sequences, in the presence or absence of two pathogens 
could be determined in a single test. The selected targets 
were the conserved region of the Mycobacterium tubercu-
losis rpoB gene and Plasmodium 18S ribosomal RNA (18S 
rRNA). After a multiplex PCR reaction, a colorimetric assay 
is performed by heating each sample up to 95°C (concen-
tration 60 μg/mL) and cooled down to 25°C in the pres-
ence of the functionalized Au-probes. The assay consist of 
a blank (sample without DNA), non-related control DNA 
and the samples. MgCl2 in a pre-determined concentration 
was added to the samples after 30 min for color develop-
ment. After measurement by UV/Vis spectroscopy, the 
aggregation profiles for each Au-nanoprobe were ana-
lyzed by comparing the absorption ratio 525 nm/600 nm. 
This method showed the capability of these particles. As 
also suggested by the authors, replacing the PCR by loop 
mediated isothermal amplification (LAMP) and the use of 
a cheap disposable platform (paper) as was already pre-
sented in another investigation of the authors (63) will 
simplify the use of this method in resource poor areas.
LAMP assays are already developed and integrated on 
microfluidic platforms as described by Luo et al. (64). They 
showed that the differentiation of bacterial strains in res-
piratory tract infections could also be done in multiplexed 
nucleic acid detection assays. The developed microfluidic 
device for LAMP was successfully used for the detection of 
H. influenza, K. pneumonia and M. tuberculosis with limits 
of detection of 17, 16 and 28 copies per μL, respectively. 
Methylene blue was used to electrochemically indicate 
the presence of double stranded DNA (65). This operation-
ally simple and potentially fast and cost-effective device 
analysed multiple genes qualitatively and quantitatively 
paves the way to multiplexed assays including other 
organisms as S. pneumoniae.
From particles, we move to silver nanorods and 
surface enhanced Raman scattering (SERS). Kotanen et al. 
(66) characterized and evaluated a handheld SERS system 
and showed that it can identify bacteria in pooled human 
sera. Different bacteria (Acinetobacter baumannii, P. aer-
uginosa, K.  pneumoniar, E. coli and Staphylococcus aureus) 
were individually inoculated into pooled human sera. 
Lysis filtration was performed to separate and isolate the 
bacteria. Silver nanorod substrates were incubated with 
the bacterial samples for 3 h at 60°C. The molecular finger-
print of each species was determined by using partial least 
squared differential and principal component analysis. 
With the device, they could were able identify bacteria at 
the species level from both serum as culture samples with 
a limit of detection of 109 CFU/mL. Identification at strain 
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level was not obtained. Therefore, it was suggested that the 
spectro meter  instrumentation needs to be at an equal level 
with the measurement sensitivity of the used nanoparti-
cles which are known to be capable of sufficient enhance-
ment factors to discriminate in between strains (67).
Even when we estimate that the actual production and 
consumable costs are too high for developing countries, 
we do see a potential for this portable device for future 
use in resource poor areas. Battery based hand-held spec-
trometers with capacities to transfer the provided bacterial 
fingerprints by satellite based Internet to a central labora-
tory is not unrealistic. For further reading about isolation 
and identification of bacteria by means of Raman spectros-
copy, see Ref. (68).
On-chip microbial growth was combined with sensi-
tive and specific surface plasmon resonance detection 
(SPR) of target antigen binding to an immobilized detec-
tion antibody (69). The fluidic-less device has the capac-
ity to culture-capture and measure bacteria as a result of 
coupling a microarray to a surface resonance imager. This 
enables the label free and real-time monitoring of bacte-
ria with a series of immobilized ligands. Different types of 
viable cells growing and dividing on chip were successfully 
detected by SPR imaging with a limit of 2.8±19.6 CFU/mL 
in the initial sample. On-chip, S. enterica, S. pneumoniae 
and E. coli O157:H7 was assayed and quantitative deter-
mination of the initial contaminating bacteria was pos-
sible (validated with standard plate counting data). The 
method developed proved to produce within only a few 
hours (with liquid or solid samples), similar results to cul-
turing methods (sensitivity and specificity) that were run 
in parallel and over several days. The developed biosensor 
has the advantage of being simply to use, needs minimal 
supplementary handling and is promising for the future 
use in resource low areas. More details about SPR can be 
found in Ref. (70).
A nanomechanical olfactory sensor system for the detec-
tion of volatiles was developed and tested (see Figure  4) 
(71, 72). This device consists of an array of silicon cantilevers 
with differential surface functionalization by polymers that 
swell upon exposure to various vapor mixtures (containing 
volatile molecules such as alcanes, alcohols, aldehydes). 
The complex nanomechanical response pattern was fed into 
an artificial neuronal network for pattern recognition. The 
diagnosis of respiratory failure was shown with a sensitiv-
ity of 83%, a specificity of 95% and a diagnostic accuracy 
of 89%. This work is followed by others who developed an 
electronic nose-on-chip to detect metabolites generated 
during infection capable for the diagnosis of ventilator-asso-
ciated pneumonia (73). Using a kernel learning method, a 
classification accuracy for the infected samples of 100% was 
reported. This device might be used for rapid diagnosis and 
might even be usable in resource poor areas.
Multiparameter testing may require expertise for 
correct interpretation, which may depend on specific clin-
ical settings, on specific markers combinations and poten-
tially on differential parameter thresholds. Advanced 
analysis strategies implemented in software and accom-
panied by suited user interfaces will therefore be an 
important complement to the actual biomarker tests.
Conclusion
The diagnosis and management of pneumococcal disease 
remains challenging, in particular in children who are 
Figure 4: Left, a differentially polymer coated cantilever array.
Any changes in the surface tension lead to bending of the cantilever and can be measured by the laser that is integrated in the system. 
Right, (top) the chip with the sensor array, (bottom) the entire analysis system [with permission from Ref. (71)].
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often asymptomatic carriers, and in low-income countries 
with a high morbidity and mortality from febrile illnesses 
caused by a range of bacteria, viruses and parasites.
New biomarkers were recently identified that add 
information about the presence as well as the invasive-
ness markers of pneumococci. Nucleic acid detection 
technology for bacteria progresses rapidly, although the 
risk of false positives due to asymptomatic bacterial colo-
nization exists.
Combining multiple parameters, e.g. adding inflam-
mation marker quantification to urine CWPS antigen detec-
tion has proven valuable in current clinical practice and 
in clinical studies to determine true positives, but there is 
room for improvement. Detection of markers of invasiveness 
(e.g. pneumolysin detection) and of specific nucleic acid 
sequences is desirable to optimize sensitivity and specificity 
in parallel, and to gather additional information about the 
threat level of the detected pathogen. Integration of multi-
ple markers into a single, rapid test could add additional 
value to the diagnostic approach. Likewise, development 
of multiparameter tests for relevant arrays of pathogens is 
important to avoid overtreatment of febrile syndromes with 
antibiotics, and such test sets might be optimized for indi-
vidual geographic or epidemiologic settings. In the best of 
all worlds and in view of the scarce resources in the devel-
oping countries and increasingly also in the healthcare 
systems of developed countries, such tests would be inex-
pensive, too, to benefit as many patients as possible.
A caveat is the antigenic and genetic drift of patho-
genic microorganisms, which may require tuning of avail-
able tests to changing epidemiologic settings, triggered 
by continuous monitoring of circulating microorganisms 
similar to what is currently done in influenza. Miniaturi-
zation of tests through the use of micro- and nanotech-
nologies is a clearly observable trend because of several 
advantages: miniaturization reduces sample require-
ments, minimizes the use of consumables, facilitates 
parallelisation, enables point-of-care use of diagnostic 
equipment and even reduces the amount of potentially 
infectious disposables, characteristics that are highly 
desirable in most healthcare settings.
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